Industriepark Mechelen Noord I, Zone L
Generaal De Wittelaan 11 A
595 articles about Galapagos NV
Landmark Bio Signs Multi-Year Agreement to Manufacture Galapagos' Oncology CAR-T Cell Therapy Clinical Programs at the Point-of-Care
Landmark Bio announced that it has signed a multi-year strategic manufacturing agreement with Galapagos NV (Euronext & NASDAQ: GLPG), an innovative biotech company with operations in Europe and the U.S.
Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023
Galapagos NV announced its financial results for the first nine months of 2023, a year-to-date business update and its outlook for the remainder of 2023.
Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma
Galapagos NV and Alfasigma S.p.A. announced that they have signed a letter of intent contemplating a transfer of the Jyseleca® business to Alfasigma, including the European and UK Marketing Authorizations, the commercial, medical and development activities for Jyseleca® and approximately 400 positions in 14 European countries.
Galapagos NV announced that during its meeting of 19 September2 023, the Board of Directors appointed Mr. Simon Sturge as Non-Executive Independent Director by way of cooptation.
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus
The GALACELA Phase 2 trial (NCT05856448) is a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of GLPG3667 in adults with active SLE.
Galapagos NV announced the appointment of Thad Huston as Chief Financial Officer and Chief Operating Officer as per 1 July 2023.
Galapagos NV announced that during its meeting of 12 June 2023, the Board of Directors co-opted Dr. Susanne Schaffert as non-executive independent Director.
Galapagos to showcase CAR-T point-of-care manufacturing and initial Phase 1/2 CLL data with CD19 CAR-T candidate, GLPG5201, at the EHA 2023 congress
Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will feature theCAR-T point-of-care manufacturing platform and will present previously disclosed initial Phase 1/2 data with CD19 CAR-T candidate, GLPG5201, at the European Hematology Association (EHA) 2023 congress, taking place from 8 June to 11June 2023 in Frankfurt, Germany.
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositis
Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient was dosed in GALARISSO, the Phase 2 dermatomyositis (DM) trial with GLPG3667.
Galapagos NV (Euronext & NASDAQ: GLPG) will present a broad range of abstracts, including analysis from randomized controlled trials (RCTs) and real-world evidence (RWE) studies at the European League Against Rheumatism (EULAR) annual congress taking place from 31 May to 3 June 2023 in Milan.
Galapagos NV announced that its Board of Directors created 1,975,000subscription rights under new subscription rightplans for the benefit of certain members ofthe personnelof the company and its subsidiaries.
Galapagos NV announced its first quarter 2023 financial results, a year-to-date business update and its outlook for the remainder of 2023.
Galapagos NV announced the departure of Bart Filius, President, Chief Operating Officer and Chief Financial Officer.
Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient was randomized inOLINGUITO, the pivotal Phase 3 program of filgotinib inAxSpA.Topline results are expected in H2 2025.
Galapagos’ shareholders approve all resolutions proposed by the Board of Directors at the annual shareholders’ meeting
Galapagos NV announces the approval of all resolutions proposed at its annual shareholders’ meeting held today at 14.00 CET.
Galapagos NV (Euronext & NASDAQ: GLPG)and NovAliX today announced a strategic collaboration in which Galapagos’ research and discovery capabilities and exclusively related employees based in Romainville, France, will be transferred toNovAliX, a drug discovery-focused Contract Research Organization.
Galapagos NV publishes its annual report for the financial year 2022 and announces its Annual Shareholders’ Meeting,to be held on Tuesday 25 April 2023, at 2:00 p.m., at the registered office of the company.
Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023
Galapagos NV (Euronext & NASDAQ: GLPG) will present new data at the European Crohn’s and Colitis Organization (ECCO) annual congress taking place from 1-4 March 2023.
Galapagos NV reports 2022 results, supported by strong adoption of Jyseleca® across Europe, and provides outlook for 2023.
Galapagos presented encouraging initial safety and efficacy data at 2023 EBMT-EHA for point-of-care manufactured CAR-T candidate, GLPG5201, in rrCLL
Galapagos NV (Euronext & NASDAQ: GLPG) today presented encouraging data at the European Society for Blood and Marrow Transplantation(EBMT)-European Hematology Association (EHA)5thEuropean CAR T-cell Meeting in Rotterdam.